Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
Fiche du document
- doi: 10.4111/icu.20200601
- issn: 2466-0493
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.4111/icu.20200601
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/34190436
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2466-054X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_11DA8B3983647
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
Prostate gland Glandula prostata Prostata Gland, Prostate Carcinoma Cancers Malignancy (Cancer) Malignant tumors Upper limb Limb, Upper Upper extremities Extremity, Upper Pectoral limbs Limb, Pectoral Thoracic limbs Extremities, Upper Upper limbs Limb, Thoracic Arms (Anatomy) Thoracic limb Upper extremity Pectoral limbCiter ce document
A. Rakauskas et al., « Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study. », Serveur académique Lausannois, ID : 10.4111/icu.20200601
Métriques
Partage / Export
Résumé
To compare the clinical outcome of males with low-risk and favorable intermediate-risk prostate cancer managed within a standardized modern protocol of active surveillance. This was a prospective cohort study with strict and expanded active surveillance criteria in males with prostate cancer. Baseline assessment included multiparametric magnetic resonance imaging (mpMRI), extended systematic biopsy, and software-based MR-targeted biopsy. Follow-up included biannual prostate-specific antigen (PSA) check, mpMRI, and control biopsy once a year for the first 2 years, and afterward mpMRI every 2 years with additional tests as clinically indicated. The primary outcome was the transition rate to active treatment. A total of 51 patients were included: 17 (33%) and 34 (67%) followed protocols of strict (study arm 1) and expanded (study arm 2) active surveillance criteria, respectively. Median age and PSA were 65 years (IQR, 60-69 years) and 5.3 ng/mL (IQR, 4.5-7.7 ng/mL), respectively. At baseline, a median of 2 (IQR, 1-3) cores were positive out of 13 (IQR, 12-14) cores; 22 males (43%) had visible mpMRI lesions. Eight males (24%) in study arm 2 had Gleason score 3+4. After a median follow-up of 36 months (IQR, 24-48 mo), no patient in study arm 1 compared with 17 patients (33%) in arm 2 underwent active treatment (p